Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Depressive Disorder, Major | 188 | 2022 | 4813 | 15.060 |
Why?
|
Antidepressive Agents | 104 | 2024 | 2912 | 11.550 |
Why?
|
Ketamine | 15 | 2023 | 527 | 4.910 |
Why?
|
Fluoxetine | 35 | 2012 | 733 | 4.050 |
Why?
|
S-Adenosylmethionine | 15 | 2015 | 219 | 3.490 |
Why?
|
Citalopram | 14 | 2018 | 402 | 3.460 |
Why?
|
Antidepressive Agents, Second-Generation | 23 | 2016 | 491 | 3.300 |
Why?
|
Piperazines | 17 | 2020 | 2548 | 2.700 |
Why?
|
Double-Blind Method | 82 | 2022 | 12451 | 2.610 |
Why?
|
Thiazoles | 9 | 2018 | 1530 | 2.270 |
Why?
|
Bupropion | 11 | 2013 | 303 | 2.230 |
Why?
|
Antipsychotic Agents | 21 | 2020 | 3078 | 2.160 |
Why?
|
Drug Therapy, Combination | 51 | 2020 | 6310 | 2.070 |
Why?
|
Randomized Controlled Trials as Topic | 42 | 2022 | 10393 | 2.020 |
Why?
|
Placebo Effect | 9 | 2022 | 516 | 1.970 |
Why?
|
Psychiatric Status Rating Scales | 49 | 2024 | 6023 | 1.580 |
Why?
|
Tetrahydrofolates | 5 | 2016 | 58 | 1.570 |
Why?
|
Anxiety | 9 | 2020 | 4670 | 1.230 |
Why?
|
Drug Resistance | 25 | 2012 | 1592 | 1.220 |
Why?
|
Depressive Disorder | 18 | 2017 | 3721 | 1.130 |
Why?
|
Dysthymic Disorder | 3 | 2011 | 73 | 1.110 |
Why?
|
Treatment Outcome | 97 | 2024 | 65295 | 1.100 |
Why?
|
Urea | 5 | 2020 | 448 | 1.080 |
Why?
|
Anxiety Disorders | 10 | 2018 | 2745 | 1.040 |
Why?
|
Antidepressive Agents, Tricyclic | 9 | 2004 | 429 | 0.970 |
Why?
|
Homocysteine | 8 | 2012 | 637 | 0.960 |
Why?
|
Cognition Disorders | 7 | 2015 | 3968 | 0.940 |
Why?
|
Somatoform Disorders | 7 | 2008 | 425 | 0.910 |
Why?
|
Vitamin B 12 | 7 | 2012 | 529 | 0.860 |
Why?
|
Adrenergic Uptake Inhibitors | 4 | 2014 | 186 | 0.850 |
Why?
|
Panic Disorder | 6 | 2020 | 613 | 0.840 |
Why?
|
Fatigue | 6 | 2013 | 1556 | 0.810 |
Why?
|
Nortriptyline | 6 | 2003 | 79 | 0.800 |
Why?
|
Adult | 129 | 2024 | 223317 | 0.760 |
Why?
|
Humans | 226 | 2024 | 767040 | 0.740 |
Why?
|
Middle Aged | 114 | 2024 | 223233 | 0.690 |
Why?
|
Piperidines | 5 | 2020 | 1667 | 0.690 |
Why?
|
Placebos | 9 | 2012 | 1660 | 0.670 |
Why?
|
Nutrition Therapy | 1 | 2021 | 101 | 0.670 |
Why?
|
Cholinergic Agents | 2 | 2017 | 97 | 0.660 |
Why?
|
Trace Elements | 1 | 2021 | 193 | 0.650 |
Why?
|
Folic Acid | 7 | 2012 | 1336 | 0.650 |
Why?
|
Sexual Dysfunction, Physiological | 5 | 2020 | 364 | 0.640 |
Why?
|
Cyclohexanols | 4 | 2013 | 126 | 0.630 |
Why?
|
Mood Disorders | 3 | 2021 | 1129 | 0.630 |
Why?
|
Receptors, Opioid, kappa | 1 | 2020 | 134 | 0.620 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 2021 | 451 | 0.620 |
Why?
|
Male | 134 | 2024 | 364203 | 0.610 |
Why?
|
Aminopyridines | 2 | 2020 | 578 | 0.610 |
Why?
|
Serotonin Agents | 1 | 2018 | 29 | 0.600 |
Why?
|
Bipolar Disorder | 6 | 2022 | 5130 | 0.600 |
Why?
|
Pyrrolidines | 1 | 2020 | 339 | 0.590 |
Why?
|
Combined Modality Therapy | 9 | 2024 | 8535 | 0.590 |
Why?
|
Female | 135 | 2024 | 396660 | 0.580 |
Why?
|
Sulfides | 2 | 2015 | 171 | 0.580 |
Why?
|
Magnetic Field Therapy | 1 | 2017 | 27 | 0.570 |
Why?
|
Severity of Illness Index | 27 | 2020 | 15925 | 0.570 |
Why?
|
S-Adenosylhomocysteine | 2 | 2014 | 40 | 0.570 |
Why?
|
Personality Inventory | 12 | 2012 | 1018 | 0.560 |
Why?
|
Akathisia, Drug-Induced | 1 | 2017 | 66 | 0.560 |
Why?
|
Treatment Failure | 12 | 2020 | 2658 | 0.550 |
Why?
|
Prolactin | 4 | 2011 | 627 | 0.540 |
Why?
|
Serotonin 5-HT2 Receptor Antagonists | 3 | 2020 | 25 | 0.540 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2017 | 165 | 0.530 |
Why?
|
Acetamides | 1 | 2018 | 259 | 0.520 |
Why?
|
Disorders of Excessive Somnolence | 4 | 2008 | 279 | 0.510 |
Why?
|
Dopamine Uptake Inhibitors | 2 | 2008 | 286 | 0.510 |
Why?
|
Dietary Supplements | 3 | 2021 | 3446 | 0.500 |
Why?
|
Hypericum | 3 | 2014 | 58 | 0.500 |
Why?
|
Cholesterol | 5 | 2004 | 2905 | 0.490 |
Why?
|
Depression | 13 | 2022 | 8234 | 0.480 |
Why?
|
Narcotic Antagonists | 1 | 2020 | 591 | 0.480 |
Why?
|
Dose-Response Relationship, Drug | 20 | 2020 | 10748 | 0.470 |
Why?
|
Hydrocortisone | 6 | 2020 | 1840 | 0.470 |
Why?
|
Glutamates | 1 | 2015 | 384 | 0.460 |
Why?
|
Benzamides | 1 | 2020 | 1376 | 0.450 |
Why?
|
Transcranial Magnetic Stimulation | 1 | 2024 | 1498 | 0.440 |
Why?
|
Aldehydes | 1 | 2014 | 170 | 0.430 |
Why?
|
Pteroylpolyglutamic Acids | 1 | 2012 | 9 | 0.410 |
Why?
|
Dibenzothiazepines | 5 | 2014 | 102 | 0.410 |
Why?
|
Patient Dropouts | 3 | 2010 | 411 | 0.410 |
Why?
|
Vitamins | 1 | 2021 | 1639 | 0.400 |
Why?
|
Infusions, Intravenous | 4 | 2022 | 2227 | 0.400 |
Why?
|
Psychomotor Agitation | 1 | 2014 | 307 | 0.390 |
Why?
|
Hyperprolactinemia | 3 | 2010 | 124 | 0.380 |
Why?
|
Mianserin | 2 | 2008 | 51 | 0.370 |
Why?
|
Libido | 2 | 2011 | 123 | 0.370 |
Why?
|
Ambulatory Care | 13 | 2006 | 2780 | 0.360 |
Why?
|
Penile Erection | 1 | 2011 | 100 | 0.360 |
Why?
|
Sertraline | 3 | 2011 | 210 | 0.360 |
Why?
|
Drug Evaluation | 1 | 2012 | 641 | 0.360 |
Why?
|
Trazodone | 2 | 2008 | 67 | 0.350 |
Why?
|
Midazolam | 3 | 2022 | 267 | 0.350 |
Why?
|
Research Design | 8 | 2016 | 6210 | 0.350 |
Why?
|
Quinolones | 4 | 2012 | 389 | 0.350 |
Why?
|
Administration, Intranasal | 2 | 2023 | 483 | 0.340 |
Why?
|
Comorbidity | 18 | 2015 | 10582 | 0.340 |
Why?
|
Clonazepam | 1 | 2010 | 135 | 0.330 |
Why?
|
Triiodothyronine | 2 | 2009 | 493 | 0.330 |
Why?
|
Adolescent | 42 | 2022 | 89046 | 0.330 |
Why?
|
Buspirone | 1 | 2009 | 80 | 0.320 |
Why?
|
Phytotherapy | 2 | 2008 | 298 | 0.320 |
Why?
|
Serotonin | 3 | 2020 | 1045 | 0.310 |
Why?
|
Suicidal Ideation | 7 | 2021 | 1467 | 0.310 |
Why?
|
Drug Administration Schedule | 10 | 2010 | 4855 | 0.310 |
Why?
|
Serotonin Receptor Agonists | 1 | 2009 | 151 | 0.310 |
Why?
|
Psychometrics | 7 | 2020 | 3060 | 0.310 |
Why?
|
Weight Gain | 2 | 2017 | 2360 | 0.300 |
Why?
|
Obesity | 6 | 2020 | 13085 | 0.300 |
Why?
|
Young Adult | 25 | 2020 | 59980 | 0.300 |
Why?
|
Social Adjustment | 2 | 2015 | 634 | 0.300 |
Why?
|
Regression Analysis | 8 | 2012 | 6331 | 0.300 |
Why?
|
Endocrine System Diseases | 1 | 2010 | 250 | 0.290 |
Why?
|
Executive Function | 2 | 2016 | 1396 | 0.290 |
Why?
|
Anti-Inflammatory Agents | 1 | 2017 | 1804 | 0.280 |
Why?
|
Plant Preparations | 1 | 2008 | 94 | 0.280 |
Why?
|
Moclobemide | 1 | 2006 | 4 | 0.280 |
Why?
|
Recurrence | 9 | 2019 | 8504 | 0.280 |
Why?
|
C-Reactive Protein | 3 | 2019 | 3851 | 0.270 |
Why?
|
Imipramine | 1 | 2006 | 96 | 0.270 |
Why?
|
Phobic Disorders | 1 | 2009 | 440 | 0.270 |
Why?
|
Mental Fatigue | 1 | 2006 | 23 | 0.270 |
Why?
|
Psychotherapy | 5 | 2018 | 1653 | 0.270 |
Why?
|
Aged | 46 | 2020 | 171319 | 0.270 |
Why?
|
Monoamine Oxidase Inhibitors | 1 | 2006 | 153 | 0.260 |
Why?
|
Complementary Therapies | 1 | 2010 | 487 | 0.260 |
Why?
|
Personality Disorders | 4 | 2009 | 726 | 0.250 |
Why?
|
Norepinephrine | 3 | 2020 | 898 | 0.250 |
Why?
|
Remission Induction | 5 | 2016 | 2408 | 0.250 |
Why?
|
Thiophenes | 2 | 2009 | 570 | 0.250 |
Why?
|
Dopamine Agents | 1 | 2006 | 186 | 0.240 |
Why?
|
Triazoles | 2 | 2008 | 903 | 0.240 |
Why?
|
Desipramine | 5 | 2004 | 183 | 0.240 |
Why?
|
Evidence-Based Medicine | 3 | 2012 | 3700 | 0.240 |
Why?
|
Cyclopropanes | 1 | 2006 | 436 | 0.240 |
Why?
|
Propylamines | 1 | 2005 | 161 | 0.230 |
Why?
|
Saliva | 1 | 2009 | 853 | 0.230 |
Why?
|
Morpholines | 1 | 2007 | 584 | 0.230 |
Why?
|
Anger | 4 | 2010 | 402 | 0.230 |
Why?
|
Drug Synergism | 4 | 2017 | 1759 | 0.220 |
Why?
|
Panic | 2 | 2019 | 103 | 0.220 |
Why?
|
Electrocardiography | 1 | 2017 | 6409 | 0.220 |
Why?
|
Analgesics, Opioid | 2 | 2017 | 3837 | 0.220 |
Why?
|
Cognition | 4 | 2019 | 7059 | 0.210 |
Why?
|
Birds | 2 | 2001 | 165 | 0.200 |
Why?
|
Demography | 3 | 2016 | 1641 | 0.200 |
Why?
|
Sample Size | 2 | 2020 | 845 | 0.200 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2011 | 2204 | 0.200 |
Why?
|
Time Factors | 16 | 2019 | 40154 | 0.190 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 7 | 2010 | 1987 | 0.190 |
Why?
|
Dopamine | 2 | 2006 | 1581 | 0.190 |
Why?
|
Leptin | 3 | 2019 | 1599 | 0.190 |
Why?
|
Feathers | 1 | 2001 | 29 | 0.180 |
Why?
|
Diagnosis, Dual (Psychiatry) | 2 | 2011 | 300 | 0.180 |
Why?
|
Lithium Carbonate | 4 | 2004 | 179 | 0.180 |
Why?
|
Affective Symptoms | 1 | 2003 | 418 | 0.170 |
Why?
|
Nervous System Diseases | 1 | 2011 | 1660 | 0.170 |
Why?
|
Suicide, Attempted | 2 | 2022 | 1413 | 0.170 |
Why?
|
Alcoholism | 1 | 2011 | 1980 | 0.170 |
Why?
|
MEDLINE | 2 | 2010 | 119 | 0.170 |
Why?
|
Nerve Net | 3 | 2017 | 2307 | 0.170 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2009 | 1495 | 0.170 |
Why?
|
Disabled Persons | 1 | 2009 | 1209 | 0.170 |
Why?
|
Recovery of Function | 1 | 2009 | 2978 | 0.160 |
Why?
|
Happiness | 1 | 2020 | 170 | 0.160 |
Why?
|
Follow-Up Studies | 13 | 2020 | 39317 | 0.160 |
Why?
|
Drug Substitution | 2 | 2020 | 292 | 0.160 |
Why?
|
Tachyphylaxis | 1 | 2018 | 54 | 0.160 |
Why?
|
Brain-Derived Neurotrophic Factor | 2 | 2019 | 606 | 0.150 |
Why?
|
Comparative Effectiveness Research | 1 | 2024 | 713 | 0.150 |
Why?
|
Receptors, Melatonin | 1 | 2018 | 31 | 0.150 |
Why?
|
Electroconvulsive Therapy | 2 | 2022 | 505 | 0.150 |
Why?
|
Testosterone | 3 | 2020 | 2490 | 0.150 |
Why?
|
Mercury | 1 | 2001 | 289 | 0.150 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.150 |
Why?
|
Globus Pallidus | 1 | 2019 | 247 | 0.150 |
Why?
|
Hostility | 2 | 2010 | 185 | 0.150 |
Why?
|
Lithium | 4 | 2004 | 600 | 0.140 |
Why?
|
Sex Characteristics | 3 | 2019 | 2647 | 0.140 |
Why?
|
Serotonin Antagonists | 1 | 2018 | 146 | 0.140 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2020 | 638 | 0.140 |
Why?
|
Clinical Trials as Topic | 5 | 2015 | 8048 | 0.140 |
Why?
|
Probability | 3 | 2010 | 2476 | 0.140 |
Why?
|
Motivation | 1 | 2007 | 2021 | 0.140 |
Why?
|
Water Pollutants, Chemical | 1 | 2001 | 356 | 0.140 |
Why?
|
Environmental Monitoring | 2 | 2001 | 1467 | 0.130 |
Why?
|
Interpersonal Relations | 2 | 2004 | 1432 | 0.130 |
Why?
|
Single-Blind Method | 1 | 2020 | 1587 | 0.130 |
Why?
|
Inflammation | 1 | 2015 | 10869 | 0.130 |
Why?
|
Excitatory Amino Acid Agents | 1 | 2015 | 26 | 0.130 |
Why?
|
Sleep Initiation and Maintenance Disorders | 3 | 2013 | 1107 | 0.130 |
Why?
|
Thiazepines | 1 | 2015 | 30 | 0.130 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2020 | 878 | 0.120 |
Why?
|
Random Allocation | 1 | 2019 | 2394 | 0.120 |
Why?
|
Predictive Value of Tests | 5 | 2015 | 15424 | 0.120 |
Why?
|
Premenopause | 1 | 2019 | 1039 | 0.120 |
Why?
|
Circadian Rhythm | 2 | 2016 | 2591 | 0.110 |
Why?
|
History, 21st Century | 2 | 2019 | 1574 | 0.110 |
Why?
|
Long-Term Care | 2 | 2016 | 631 | 0.110 |
Why?
|
Neurogenesis | 1 | 2020 | 863 | 0.110 |
Why?
|
Brain | 7 | 2016 | 27163 | 0.110 |
Why?
|
Receptors, Serotonin | 1 | 2014 | 210 | 0.110 |
Why?
|
Adiponectin | 2 | 2019 | 1115 | 0.110 |
Why?
|
Mental Disorders | 3 | 2010 | 6873 | 0.110 |
Why?
|
Plant Extracts | 2 | 2014 | 496 | 0.110 |
Why?
|
Confidence Intervals | 2 | 2011 | 2920 | 0.110 |
Why?
|
Drug Monitoring | 1 | 2019 | 963 | 0.100 |
Why?
|
Odds Ratio | 3 | 2011 | 9660 | 0.100 |
Why?
|
European Union | 1 | 2013 | 158 | 0.100 |
Why?
|
One-Carbon Group Transferases | 1 | 2012 | 6 | 0.100 |
Why?
|
Carnitine | 1 | 2014 | 253 | 0.100 |
Why?
|
Reference Values | 3 | 2016 | 4918 | 0.100 |
Why?
|
Aging | 1 | 2011 | 8729 | 0.100 |
Why?
|
Personality Assessment | 2 | 2005 | 646 | 0.100 |
Why?
|
Outpatients | 2 | 2019 | 1600 | 0.100 |
Why?
|
Histamine | 1 | 2014 | 496 | 0.100 |
Why?
|
Sleep Stages | 2 | 2006 | 705 | 0.100 |
Why?
|
Radioimmunoassay | 2 | 2009 | 861 | 0.100 |
Why?
|
Suicide | 1 | 2003 | 1606 | 0.100 |
Why?
|
Benzodiazepines | 3 | 2022 | 1137 | 0.100 |
Why?
|
Research | 2 | 2018 | 1977 | 0.090 |
Why?
|
Biological Availability | 1 | 2012 | 387 | 0.090 |
Why?
|
Thalamus | 1 | 2017 | 1040 | 0.090 |
Why?
|
Prevalence | 6 | 2012 | 15851 | 0.090 |
Why?
|
History, 20th Century | 1 | 2019 | 2765 | 0.090 |
Why?
|
Resistin | 1 | 2011 | 172 | 0.090 |
Why?
|
alpha 1-Antitrypsin | 1 | 2011 | 169 | 0.090 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2012 | 276 | 0.090 |
Why?
|
Light | 1 | 2016 | 1358 | 0.090 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2006 | 3724 | 0.090 |
Why?
|
Databases, Bibliographic | 1 | 2010 | 128 | 0.090 |
Why?
|
Apolipoprotein C-III | 1 | 2011 | 209 | 0.090 |
Why?
|
Antimanic Agents | 2 | 2004 | 524 | 0.090 |
Why?
|
Fluvoxamine | 1 | 2010 | 77 | 0.090 |
Why?
|
Neuropsychological Tests | 2 | 2015 | 7121 | 0.090 |
Why?
|
Addison Disease | 1 | 2010 | 48 | 0.090 |
Why?
|
Prospective Studies | 7 | 2018 | 54886 | 0.080 |
Why?
|
Hypnotics and Sedatives | 1 | 2018 | 1193 | 0.080 |
Why?
|
Methionine | 1 | 2012 | 570 | 0.080 |
Why?
|
Receptors, Tumor Necrosis Factor, Type II | 1 | 2011 | 347 | 0.080 |
Why?
|
Analysis of Variance | 4 | 2013 | 6215 | 0.080 |
Why?
|
Postmenopause | 1 | 2019 | 2518 | 0.080 |
Why?
|
Interleukin-6 | 2 | 2019 | 3227 | 0.080 |
Why?
|
Statistics as Topic | 2 | 2007 | 2350 | 0.080 |
Why?
|
Paroxetine | 1 | 2010 | 181 | 0.080 |
Why?
|
Child of Impaired Parents | 2 | 2003 | 462 | 0.080 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2011 | 12250 | 0.080 |
Why?
|
Methadone | 1 | 2011 | 317 | 0.080 |
Why?
|
Drug Discovery | 1 | 2017 | 1068 | 0.080 |
Why?
|
Epidermal Growth Factor | 1 | 2011 | 697 | 0.080 |
Why?
|
Peroxidase | 1 | 2011 | 610 | 0.080 |
Why?
|
Eicosapentaenoic Acid | 2 | 2009 | 565 | 0.080 |
Why?
|
Lepidium | 1 | 2008 | 8 | 0.080 |
Why?
|
Italy | 1 | 2010 | 856 | 0.070 |
Why?
|
Hyperthyroidism | 1 | 2010 | 292 | 0.070 |
Why?
|
Secondary Prevention | 3 | 2010 | 1472 | 0.070 |
Why?
|
Pharmacogenetics | 1 | 2012 | 682 | 0.070 |
Why?
|
Child Behavior Disorders | 2 | 2003 | 812 | 0.070 |
Why?
|
Cardiovascular Diseases | 3 | 2011 | 15645 | 0.070 |
Why?
|
Endpoint Determination | 1 | 2010 | 592 | 0.070 |
Why?
|
Pituitary ACTH Hypersecretion | 1 | 2010 | 180 | 0.070 |
Why?
|
Quality of Life | 2 | 2013 | 13485 | 0.070 |
Why?
|
Terminology as Topic | 2 | 2006 | 1540 | 0.070 |
Why?
|
Anti-Anxiety Agents | 1 | 2010 | 405 | 0.070 |
Why?
|
Lithium Compounds | 1 | 2009 | 226 | 0.070 |
Why?
|
Heart Rate | 1 | 2018 | 4209 | 0.070 |
Why?
|
Prefrontal Cortex | 1 | 2017 | 2224 | 0.070 |
Why?
|
Opiate Substitution Treatment | 1 | 2011 | 452 | 0.070 |
Why?
|
PubMed | 1 | 2007 | 129 | 0.070 |
Why?
|
Body Mass Index | 2 | 2020 | 13048 | 0.070 |
Why?
|
Age Factors | 5 | 2011 | 18401 | 0.070 |
Why?
|
Risk Factors | 8 | 2010 | 74886 | 0.070 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2010 | 497 | 0.060 |
Why?
|
Aptitude | 1 | 2006 | 43 | 0.060 |
Why?
|
Polycystic Ovary Syndrome | 1 | 2010 | 383 | 0.060 |
Why?
|
Logistic Models | 5 | 2009 | 13284 | 0.060 |
Why?
|
Case-Control Studies | 4 | 2019 | 22254 | 0.060 |
Why?
|
Juvenile Delinquency | 2 | 2003 | 115 | 0.060 |
Why?
|
Evoked Potentials | 1 | 2011 | 1050 | 0.060 |
Why?
|
Hypothyroidism | 1 | 2010 | 667 | 0.060 |
Why?
|
Dominance, Cerebral | 2 | 2016 | 616 | 0.060 |
Why?
|
Impulsive Behavior | 2 | 2019 | 345 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2531 | 0.060 |
Why?
|
Pilot Projects | 4 | 2011 | 8732 | 0.060 |
Why?
|
Patients | 1 | 2011 | 908 | 0.060 |
Why?
|
Mental Recall | 1 | 2011 | 1218 | 0.060 |
Why?
|
Nausea | 1 | 2008 | 682 | 0.060 |
Why?
|
Physician-Patient Relations | 2 | 2016 | 3266 | 0.060 |
Why?
|
Nervous System | 1 | 2008 | 543 | 0.060 |
Why?
|
Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2811 | 0.060 |
Why?
|
Aged, 80 and over | 4 | 2011 | 59548 | 0.060 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2012 | 3552 | 0.060 |
Why?
|
Serotonin 5-HT1 Receptor Agonists | 1 | 2004 | 42 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2015 | 4349 | 0.060 |
Why?
|
Retreatment | 1 | 2005 | 598 | 0.050 |
Why?
|
Sex Factors | 3 | 2007 | 10622 | 0.050 |
Why?
|
Fenfluramine | 1 | 2003 | 58 | 0.050 |
Why?
|
Problem Solving | 1 | 2006 | 442 | 0.050 |
Why?
|
Students | 1 | 2013 | 1744 | 0.050 |
Why?
|
Greece | 2 | 2001 | 340 | 0.050 |
Why?
|
Androgens | 1 | 2009 | 1281 | 0.050 |
Why?
|
Checklist | 1 | 2009 | 842 | 0.050 |
Why?
|
Medication Adherence | 2 | 2010 | 2191 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2012 | 4247 | 0.050 |
Why?
|
Gastrointestinal Diseases | 1 | 2010 | 1205 | 0.050 |
Why?
|
Genetic Markers | 1 | 2008 | 2602 | 0.050 |
Why?
|
Docosahexaenoic Acids | 1 | 2008 | 914 | 0.050 |
Why?
|
Drug Therapy | 1 | 2004 | 504 | 0.050 |
Why?
|
Nesting Behavior | 1 | 2001 | 15 | 0.050 |
Why?
|
Sleep | 1 | 2016 | 4816 | 0.040 |
Why?
|
Attitude of Health Personnel | 1 | 2014 | 3928 | 0.040 |
Why?
|
Fatty Acids, Omega-3 | 1 | 2010 | 1399 | 0.040 |
Why?
|
Psychoses, Substance-Induced | 1 | 2021 | 98 | 0.040 |
Why?
|
Prognosis | 3 | 2008 | 29963 | 0.040 |
Why?
|
Likelihood Functions | 1 | 2003 | 996 | 0.040 |
Why?
|
Electroencephalography | 2 | 2011 | 6282 | 0.040 |
Why?
|
Genotype | 1 | 2014 | 13035 | 0.040 |
Why?
|
Hypercholesterolemia | 2 | 2005 | 1144 | 0.040 |
Why?
|
Self Report | 1 | 2011 | 3773 | 0.040 |
Why?
|
Psychotropic Drugs | 1 | 2004 | 881 | 0.040 |
Why?
|
Cost-Benefit Analysis | 1 | 2012 | 5537 | 0.040 |
Why?
|
Drug Prescriptions | 2 | 2006 | 1664 | 0.040 |
Why?
|
Benzhydryl Compounds | 1 | 2006 | 944 | 0.040 |
Why?
|
Dissociative Disorders | 1 | 2021 | 234 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2006 | 2428 | 0.040 |
Why?
|
Headache | 1 | 2006 | 1261 | 0.040 |
Why?
|
Risk Assessment | 2 | 2010 | 24299 | 0.040 |
Why?
|
Retrospective Studies | 6 | 2006 | 81659 | 0.040 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2009 | 2764 | 0.040 |
Why?
|
Data Interpretation, Statistical | 1 | 2007 | 2698 | 0.040 |
Why?
|
Disability Evaluation | 1 | 2004 | 1829 | 0.030 |
Why?
|
Personnel Staffing and Scheduling | 1 | 2021 | 497 | 0.030 |
Why?
|
Central Nervous System Stimulants | 1 | 2006 | 1168 | 0.030 |
Why?
|
Physicians | 1 | 2014 | 4593 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 5 | 2020 | 36582 | 0.030 |
Why?
|
Opioid-Related Disorders | 1 | 2011 | 2188 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2011 | 14672 | 0.030 |
Why?
|
Ranidae | 1 | 1996 | 32 | 0.030 |
Why?
|
Population Surveillance | 1 | 2006 | 2594 | 0.030 |
Why?
|
Psychotic Disorders | 2 | 2009 | 3275 | 0.030 |
Why?
|
Color | 1 | 2016 | 296 | 0.030 |
Why?
|
Child | 3 | 2022 | 80771 | 0.030 |
Why?
|
Pesticide Residues | 1 | 1996 | 95 | 0.030 |
Why?
|
Activities of Daily Living | 1 | 2004 | 2429 | 0.030 |
Why?
|
Hydrocarbons, Chlorinated | 1 | 1996 | 120 | 0.030 |
Why?
|
Osteoporosis | 1 | 2004 | 1604 | 0.030 |
Why?
|
Magic | 1 | 1994 | 14 | 0.030 |
Why?
|
Triglycerides | 1 | 2003 | 2444 | 0.030 |
Why?
|
Chronic Disease | 2 | 2007 | 9362 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2005 | 2783 | 0.030 |
Why?
|
Insecticides | 1 | 1996 | 203 | 0.030 |
Why?
|
Diabetes Mellitus | 2 | 2010 | 5886 | 0.030 |
Why?
|
Bone and Bones | 1 | 2004 | 2587 | 0.030 |
Why?
|
Gyrus Cinguli | 1 | 2020 | 1118 | 0.030 |
Why?
|
Body Weight | 1 | 2004 | 4627 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 12986 | 0.030 |
Why?
|
Autonomic Nervous System | 1 | 2018 | 707 | 0.030 |
Why?
|
Body Temperature | 1 | 2016 | 780 | 0.030 |
Why?
|
Monitoring, Physiologic | 1 | 2021 | 1794 | 0.030 |
Why?
|
Republic of Korea | 1 | 2015 | 591 | 0.030 |
Why?
|
Longitudinal Studies | 2 | 2020 | 14766 | 0.030 |
Why?
|
Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 326 | 0.030 |
Why?
|
Statistics, Nonparametric | 2 | 2012 | 2850 | 0.030 |
Why?
|
Least-Squares Analysis | 1 | 2013 | 369 | 0.030 |
Why?
|
Age of Onset | 3 | 2005 | 3344 | 0.030 |
Why?
|
Schizophrenia | 2 | 2008 | 6977 | 0.030 |
Why?
|
Cytokines | 1 | 2007 | 7446 | 0.020 |
Why?
|
Science | 1 | 1994 | 234 | 0.020 |
Why?
|
Health Status | 1 | 2004 | 4091 | 0.020 |
Why?
|
Melatonin | 1 | 2016 | 670 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2006 | 3449 | 0.020 |
Why?
|
Linear Models | 1 | 2020 | 5875 | 0.020 |
Why?
|
Animals | 5 | 2014 | 168965 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2105 | 0.020 |
Why?
|
Epilepsy | 2 | 1997 | 3317 | 0.020 |
Why?
|
Delayed-Action Preparations | 1 | 2014 | 965 | 0.020 |
Why?
|
Cost of Illness | 2 | 2013 | 1951 | 0.020 |
Why?
|
History, Ancient | 2 | 2003 | 213 | 0.020 |
Why?
|
Patient Selection | 1 | 2021 | 4256 | 0.020 |
Why?
|
Overweight | 1 | 2020 | 2448 | 0.020 |
Why?
|
Feeding Behavior | 1 | 2001 | 3207 | 0.020 |
Why?
|
Hypertension | 3 | 2021 | 8615 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2006 | 26325 | 0.020 |
Why?
|
Universities | 1 | 2013 | 1004 | 0.020 |
Why?
|
Plant Roots | 1 | 2008 | 121 | 0.020 |
Why?
|
Gas Chromatography-Mass Spectrometry | 1 | 2008 | 355 | 0.020 |
Why?
|
Administration, Cutaneous | 1 | 2009 | 715 | 0.020 |
Why?
|
Cross-Cultural Comparison | 1 | 2010 | 638 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2004 | 20169 | 0.020 |
Why?
|
Chi-Square Distribution | 2 | 2003 | 3431 | 0.020 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2008 | 193 | 0.020 |
Why?
|
Consensus | 2 | 2006 | 3207 | 0.020 |
Why?
|
Drug Combinations | 1 | 2012 | 2086 | 0.020 |
Why?
|
Primary Health Care | 2 | 2014 | 4746 | 0.020 |
Why?
|
Empirical Research | 1 | 2005 | 119 | 0.020 |
Why?
|
Controlled Clinical Trials as Topic | 1 | 2006 | 187 | 0.010 |
Why?
|
Substance-Related Disorders | 1 | 2021 | 4422 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2010 | 935 | 0.010 |
Why?
|
Drug Costs | 1 | 2012 | 1196 | 0.010 |
Why?
|
History, Early Modern 1451-1600 | 1 | 2003 | 3 | 0.010 |
Why?
|
History, Modern 1601- | 1 | 2003 | 16 | 0.010 |
Why?
|
Self-Assessment | 1 | 2006 | 400 | 0.010 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2016 | 3370 | 0.010 |
Why?
|
Chemokines | 1 | 2007 | 963 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5363 | 0.010 |
Why?
|
Cooperative Behavior | 1 | 2010 | 1512 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2012 | 2006 | 0.010 |
Why?
|
Drug Delivery Systems | 1 | 2013 | 2212 | 0.010 |
Why?
|
Achievement | 1 | 2003 | 287 | 0.010 |
Why?
|
United States | 1 | 2009 | 72971 | 0.010 |
Why?
|
Brain Mapping | 1 | 2016 | 6597 | 0.010 |
Why?
|
Practice Guidelines as Topic | 2 | 2010 | 7435 | 0.010 |
Why?
|
Fatty Acids | 1 | 2008 | 1806 | 0.010 |
Why?
|
Creatinine | 1 | 2005 | 1916 | 0.010 |
Why?
|
Health Care Costs | 1 | 2012 | 3239 | 0.010 |
Why?
|
Smoking | 2 | 2005 | 9081 | 0.010 |
Why?
|
Patient Care Team | 1 | 2010 | 2516 | 0.010 |
Why?
|
Hypogonadism | 1 | 2004 | 805 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2006 | 1278 | 0.010 |
Why?
|
Lipids | 1 | 2009 | 3322 | 0.010 |
Why?
|
Acute Disease | 1 | 2007 | 7236 | 0.010 |
Why?
|
Greek World | 1 | 1994 | 6 | 0.010 |
Why?
|
Eggs | 1 | 1996 | 182 | 0.010 |
Why?
|
Anticonvulsants | 1 | 2004 | 1921 | 0.010 |
Why?
|
Iraq | 1 | 1994 | 93 | 0.010 |
Why?
|
Sexual Behavior | 1 | 2004 | 2196 | 0.010 |
Why?
|
Mass Screening | 1 | 2010 | 5456 | 0.010 |
Why?
|
Models, Theoretical | 1 | 2006 | 3561 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2005 | 4045 | 0.010 |
Why?
|
Species Specificity | 1 | 1996 | 2412 | 0.010 |
Why?
|
Bone Density | 1 | 2004 | 3573 | 0.010 |
Why?
|
Data Collection | 1 | 2001 | 3321 | 0.010 |
Why?
|
Blood Glucose | 1 | 2006 | 6421 | 0.010 |
Why?
|
Stress, Psychological | 1 | 2006 | 4526 | 0.010 |
Why?
|
Functional Laterality | 1 | 1997 | 2245 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 41718 | 0.010 |
Why?
|
Boston | 1 | 2003 | 9360 | 0.010 |
Why?
|
Algorithms | 1 | 2010 | 14098 | 0.000 |
Why?
|
Cerebral Cortex | 1 | 1997 | 5754 | 0.000 |
Why?
|
Hospitalization | 1 | 1997 | 10815 | 0.000 |
Why?
|